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Palmitoylation is a prevalent feature amongst G protein-coupled receptors. In this study we sought to establish whether the TPα and TPβ
isoforms of the human prostanoid thromboxane (TX) A2 receptor (TP) are palmitoylated and to assess the functional consequences thereof.
Consistent with the presence of three cysteines within its unique carboxyl-terminal domain, metabolic labelling and site-directed mutagenesis
confirmed that TPβ is palmitoylated at Cys347 and, to a lesser extent, at Cys373,377 whereas TPα is not palmitoylated. Impairment of
palmitoylation did not affect TPβ expression or its ligand affinity. Conversely, agonist-induced [Ca2+]i mobilization by TPβ
C347S and the non-
palmitoylated TPβC347,373,377S, but not by TPβC373S or TPβC373,377S, was significantly reduced relative to the wild type TPβ suggesting that
palmitoylation at Cys347 is specifically required for efficient Gq/phospholipase Cβ effector coupling. Furthermore, palmitoylation at Cys373,377 is
critical for TPβ internalization with TPβC373S, TPβC373,377S and TPβC347,373,377S failing to undergo either agonist-induced or temperature-
dependent tonic internalization. On the other hand, whilst TPβC347S underwent reduced agonist-induced internalization, it underwent tonic
internalization to a similar extent as TPβ. The deficiency in agonist-induced internalization by TPβC347S, but not by TPβC373,377 nor
TPβC347,373,377S, was overcome by over-expression of either β-arrestin1 or β-arrestin2. Taken together, data herein suggest that whilst
palmitoylation of TPβ at Cys373,377 is critical for both agonist- and tonic-induced internalization, palmitoylation at Cys347 has a role in
determining which pathway is followed, be it by the β-arrestin-dependent agonist-induced pathway or by the β-arrestin-independent tonic
internalization pathway.
© 2006 Elsevier Inc. Open access under CC BY license.Keywords: Thromboxane A2 receptor; Receptor internalization; Palmitoylation1. Introduction
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Open access under CC BY license.interactions [1,2]. Common lipidations include the co-transla-
tional attachment of myristate acid via a stable amide linkage to
amino (N)-terminal glycine residues, post-translational attach-
ment of farnesyl or geranylgeranyl isoprenoids to carboxy (C)-
terminal cysteine(s) via thioether bond(s) and post-translational
addition of palmitate or other fatty acyl group to cysteine(s) via
labile thioester linkages [1–5]. The latter, generally referred to as
palmitoylation but more accurately termed acyl thioesterifica-
tion or S-acylation, is the least understood despite being the most
common lipid modification [6]. Unlike myristoylation or
isoprenylation, palmitoylation is a dynamic modification with
proteins constantly undergoing enzymatic cycles of palmitoyla-
tion and depalmitoylation, events that are thought to regulate not
only membrane/protein interactions but also protein function
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candidate mammalian protein:S-acyl-transferases (PATs) and S-
acylprotein thioesterases (APTs) that catalyze such palmitoyla-
tions and depalmitoylations, respectively [5,6].
A diverse range of palmitoylated proteins have been iden-
tified, most notably amongst proteins participating in intracel-
lular signalling including H- and N-Ras, endothelial nitric oxide
synthase, growth cone-associated protein 43, SRC and several
other protein tyrosine kinases ([4,5] and references therein).
Palmitoylation is also a feature of heterotrimeric Gα subunits
and of their downstream effectors, including Gαs, Gαq and
adenylyl cyclase [1,4,5] and is a common modification of
numerous G protein-coupled receptors (GPCRs). In fact, it is
estimated that up to 80% of GPCRs contain at least one
palmitoylable cysteine typically located some 10–14 amino acid
residues downstream from transmembrane (TM) 7 within their
carboxyl-terminal (C)-tail domain [7]. Rhodopsin, the first
GPCR to be confirmed to be palmitoylated, undergoes pal-
mitoylation at Cys322 and Cys323 within its C-tail domain and it
was proposed that interaction of the hydrophobic palmitoyl
moieties with the lipid bilayer of the plasma membrane may
result in the formation of a fourth intracellular loop within its
GPCR structure [8]. Numerous other GPCRs have since been
shown to be palmitoylated within their C-tail domains including
the α2A- and β2-adrenergic receptors [9,10], the dopamine D1
receptor [11,12], the 5-hydroxytryptamine (4a) receptor [13], the
muscarinic acetylcholine receptor [14], the prostacyclin receptor
[15] and the vasopressin V1A and V2 receptors [16,17]. Through
these and many other specific examples, it is evident that while
palmitoylation may potentially affect diverse aspects of GPCR
function and regulation including processing and targeting,
protein turnover, G protein coupling, phosphorylation and
desensitization, sequestration and/or internalization [1–5], it is
also apparent that such effects are generally receptor specific,
requiring investigation at the individual GPCR level.
The prostanoid thromboxane (TX)A2 plays a critical role in
vascular hemostasis regulating platelet activation status and
vascular tone [18]. In humans, but not in non-primates, TXA2
signals through two distinct isoforms of the TXA2 receptor (TP)
termed TPα and TPβ [18–21]. As members of the GPCR
superfamily, TPα and TPβ are identical for their first N-terminal
328 amino acids and diverge exclusively within their carboxyl-
terminal (C)-tail domains [18–22]. While TPα and TPβ arise by
differential splicing [20], they display distinct patterns of
mRNA and protein expression [23,24] and, more recently, it has
been established that they are under the transcriptional regu-
lation of distinct promoters within the single human TP gene
[25–28]. Moreover, whilst both TPα and TPβ exhibit identical
ligand binding and Gq-dependent activation of phospholipase
(PL) Cβ, their primary effector [20,29–31], they oppositely
regulate adenylyl cyclase through Gs and Gi, respectively [32]
and TPα, but not TPβ, can couple to Gh/tissue transglutaminase
activation [33].
Hence, it is evident that TPα and TPβ display differences in
their patterns of expression and in their modes of intracellular
signalling, suggesting that they may have distinct physiologic
roles [22]. Consistent with this hypothesis, there is an abundanceof emerging evidence suggesting that the greatest differences
between TPα and TPβ lies in their modes of desensitization/
regulation post-receptor signalling, through events that are largely
regulated through sequences or functional determinants within
their respective unique C-tail domains. For example, while both
TPs undergo agonist-induced phosphorylation [24,29], TPβ, but
not TPα, is subject to both agonist-induced and tonic internal-
ization [34,35]. Agonist-induced TPβ internalization appears to
be dynamin-, GRK2/3- and β-arrestin-dependent [34,35],
requiring an active or dynamic actin cytoskeleton [36] and may
also involve direct interaction between Rab 11 and the C-tail
domain of TPβ [37]. On the other hand, tonic internalization of
TPβ is both GRK- and β-arrestin-independent but dynamin-
dependent and is also dependent on the presence of an intact
internalization motif within its C-tail domain [34,35]. In studies
investigating cross-talk between TXA2 and other prostanoids, it
was established that signalling by TPα, but not TPβ, is subject to
prostacyclin- and prostaglandin (PG)D2-mediated desensitization
involving direct PKA phosphorylation of TPα at Ser329 within its
unique C-tail domain [30,38]. Consistent with this, TPα, but not
the TPβ, is also a target for nitric oxide (NO)-induced desen-
sitization that occurs through a mechanism involving its direct
PKG phosphorylation at Ser331 within its unique C-tail domain
[39]. These latter studies point to an essential role for TPα in
prostacyclin- and NO-regulated vascular hemostasis and point to
a redundant or an, as yet, unidentified role for TPβ in this essential
physiologic process [22,30,38,39]. Moreover, collectively, these
data also indicate that TPα and TPβ are subject to distinct modes
of regulation, intracellular signalling and expression and that such
differences are largely determined by sequences within their
unique C-tail domains.
Another notable difference between the TP isoforms, the
significance of which has yet to be investigated, is the presence
of multiple cysteine (Cys) residues within the unique C-tail of
TPβ at Cys347, Cys373 and Cys377, while the C-tail domain of
the TPα is entirely devoid of such residues. The presence of Cys
residues within the unique C-tail domain of TPβ raises the
possibility that they may be palmitoylated and that such
modification(s) may contribute to the functional differences
between the two TP isoforms. Hence, the aim of the current
study was to investigate whether TPβ is subject to palmitoyla-
tion and to examine the functional consequences thereof. Our
studies confirm that TPβ, but not TPα, is palmitoylated at
Cys347 and, to a lesser extent, at Cys373/377, a modification that
not only regulates agonist-induced second messenger signalling
but also differentially influences agonist- and tonic-induced
internalization of TPβ.
2. Experimental procedures
2.1. Materials
U46619 and SQ29,548 were obtained from Cayman Chemical Company.
G418 sulfate and FURA2/AM were from Calbiochem. [3H]SQ29,548 (50.4 Ci/
mmol) was obtained from DuPont NEN. Rat monoclonal 3F10 anti-HA-horse
radish peroxidase-conjugated antibody (25 μg/ml) was obtained from Roche.
Mouse monoclonal anti-hemagglutinin (HA)-101R antibody (1 mg/ml) was
obtained from Eurogentec; goat anti-β-arrestin1 (K-16), goat anti-β-arrestin2
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HRP-conjugated mouse anti-goat (400 μg/ml) and HRP-conjugated goat anti-
rabbit (400 μg/ml) secondary antibodies were from Santa Cruz; goat anti-mouse
FITC-conjugated antibody, propidium iodide, protein G sepharose 4B Fast Flow
(∼50% v/v slurry) were obtained from Sigma. AlexaFluor594 goat anti-mouse
antibody (2 mg/ml) was fromMolecular Probes. [9, 10-3H] Palmitic acid (60 Ci/
mmol) was purchased from TOCRIS.
2.2. Site-directed mutagenesis of TPβ to generate TPβC347S, TPβC373S,
TPβC373,377S and TPβC347,373,377S
The plasmids pHM6:TPα, pHM6:TPβ and pHM6:hIP encoding HA
epitope-tagged forms of TPα, TPβ and human prostacyclin receptor (IP),
respectively, were previously described [30,40]. pRK5:β-arrestin1, pcDNA3:β-
arrestin2, pEGFPN3:β-arrestin1 and pEGFPN1:β-arrestin2 encoding wild type
and green fluorescent protein (GFP)-tagged forms of β-arrestin1 and β-arrestin2
have been described [41–43]. pCMV:Gαq, encoding Gαq, has been previously
described [40,44].
Conversion of Cys347 to Ser347 of TPβ to generate pHM6:TPβC347S was
achieved using pHM6:TPβ as template and the sense/antisense primer pair (5′ G
ATC TCG GCT CAC TCC AAC CTC CGC CTC). Conversion of Cys373 to
Ser373 to generate pHM6:TPβC373S was achieved using pHM6:TPβ as template
and the sense/antisense primer pair (5′ GTA AGC CAC TCC GCC CGG CCT
TGC). Conversion of Cys373,377 to Ser373,377 to generate pHM6:TPβC373,377S
was performed using pHM6:TPβ as template and the sense/antisense primer pair
(5′GTAAGCCAC TCCGCCCGGCCT TCCATGCTC TTTG). The plasmid
pHM6:TPβC347,373,377S was generated using pHM6:TPβC347S as template and
sense/antisense primer pair (5′GTAAGCCAC TCCGCCCGGCCT TCCATG
CTC TTT G). For each primer pair, sequences shown correspond to the sense
primer and the identity of the mutator codon is in boldface italics. All site-directed
mutagenesis was performed using QuikChange™ (Stratagene) site-directed
mutagenesis and all mutations were validated by DNA sequence analysis.
2.3. Cell culture and transfections
Human embryonic kidney (HEK) 293 cells were obtained from the
American Type Culture Collection and were grown in minimal essential
medium (MEM) containing 10% foetal bovine serum (FBS).
Routinely, approximately 48 h prior to transfection cells were plated at a
density of 2×106 cells/10 cm culture dish in 8 ml media. Thereafter, cells were
transiently transfected with 10 μg of pADVA [45] and 25 μg of pCMV- or pHM-
based vectors using the calcium phosphate/DNA co-precipitation procedure, as
previously described [44]. For transient transfections, cells were harvested 48 h
after transfection. To create stable cell lines, HEK 293 cells were transfected
with 10 μg Sca1 linearized pADVA plus 25 μg Sca1 linearized pHM-based
vectors. Forty-eight hours post-transfection, G418 (0.8 mg/ml) was added;
individual G418 resistant colonies were selected after approximately 21 days
and clonal cell lines were expanded and were assessed for TP expression by
radioligand binding assay using the radioligand [3H]SQ29,548. In this way,
HEK.TPβC347S, HEK.TPβC373S, HEK.TPβC373,377S and HEK.TPβC347,373,377S
cell lines stably over-expressing HA-tagged forms of TPβC347S, TPβC373S,
TPβC373,377S and TPβC347,373,377S, respectively, were established. HEK.TPα,
HEK.TPβ and HEK.hIP cells stably over-expressing HA-tagged form of TPα,
TPβ and of the human IP, respectively, have been previously described [30,40].
2.4. Radioligand binding studies
TP radioligand binding assays were carried out at 30 °C for 30 min in the
presence of 0–40 nM [3H]SQ29,548 for Scatchard analyses or in the presence of
20 nM [3H]SQ29,548 for saturation radioligand binding experiments as
previously described [44]. Protein determinations were carried out using the
Bradford assay.
2.5. Palmitoylation of the thromboxane receptor
Palmitoylation was carried out essentially as previously described [15].
Briefly, cells were plated 48 h in advance to achieve a density of approx.3×105 cells/10-cm dish (∼80% confluency) on the day of metabolic labelling.
Cells were washed once in PBS and then metabolically labelled in serum-free
MEM (1.5 ml) containing 1.5 mCi of [3H] palmitic acid (60 Ci/mmol).
Following incubation for 2 h at 37 °C, the labelling reaction was stopped by
washing the cells in ice-cold PBS. Thereafter, cells were lysed by the addition of
600 μl RIPA buffer (20 mM Tris–Cl, pH 8.0, 0.15 M NaCl, 1% Triton X-100,
1% SDS, 1% deoxycholate, 10 mM EDTA, pH 8.0, 1 mM PMSF, 2 mM 1,10-
phenanthroline, 10 μg/ml aprotinin, 10 μg/ml antipain, 1 μg/ml leupeptin,
10 μg/ml benzamidine) and were disrupted by passing through needles of
decreasing bore size. The lysate was centrifuged at 13,000 rpm for 5 min and the
supernatant (600–700 μg) was subjected to immunoprecipitation using the anti-
HA 101R antibody (1:300 dilution) followed by the addition of 10 μl protein G
Sepharose 4B (50% v/v slurry) and further incubation at room temperature for
1 h, as described [15]. Immunoprecipitates were then resuspended in SDS-
PAGE sample buffer (25 mM Tris–Cl, pH 8.0, 1% SDS, 5% glycerol, 0.0013%
(w/v) Bromophenol Blue, 1% β-Mercaptoethanol), incubated at room
temperature for 15 min, and then resolved by 8% SDS-PAGE. After
electroblotting onto PVDF membrane, the blots were soaked in Amplify
(Amersham) for 30 min followed by fluorography using Kodak X-Omat XAR
film for 60 days at −70 °C. Thereafter, following fluorographic exposure, PVDF
membranes were screened by immunoblot analysis using the anti-HA 3F10
peroxidase-conjugated antibody followed by chemiluminescence detection.
2.6. Calcium measurements
Measurements of agonist-induced intracellular calcium ([Ca2+]i) mobiliza-
tion in response to the TXA2 mimetic U46619 (1 μM) were carried out in
FURA2/AM preloaded HEK.TPβ, HEK.TPβC347S, HEK.TPβC373S, HEK.
TPβC373,377S and HEK.TPβC347,373,377S cells that had been transiently co-
transfected with pCMV:Gαq and pADVA some 48 h previously, essentially as
described [44]. The agonist U46619, in ethanol, was diluted 1:1000 in the
vehicle HBSSHB (modified Ca2+/Mg2+-free Hank's buffered salt solution,
containing 10 mM HEPES, pH 7.67, 0.1% bovine serum albumin) and the
agonist in vehicle (20 μl) or, as controls, the vehicle alone (20 μl) were added to
the 2 ml cells (0.8×106 cells/ml) to achieve the desired working concentration. It
was established that the vehicle had no effect on [Ca2+]i mobilization by either
TP isoform and had no effect on experimental data. The ratio of the fluorescence
at 340 nm to 380 nm is a measure of [Ca2+]i [46], assuming a Kd of 225 nM Ca
2+
for FURA2/AM. The results presented in the figures are representative data from
at least three/four independent experiments and are plotted as changes in
intracellular Ca2+ mobilized (Δ[Ca2+]i (nM)) as a function of time (seconds, s)
following agonist stimulation.
2.7. Internalization of TP receptors
Cells were seeded at a density of 5×104 cells/ml per well in 1 ml of MEM,
10% FBS media into 24-well plates, which had been pre-coated with 0.001%
poly-L-lysine. The cells were then incubated for 48 h at 37 °C prior to
experiments. To assess agonist-induced internalization of TPβ or its mutated
derivatives, the media was changed to serum-free Dulbecco's modified essential
medium and thereafter, cells were treated with 1 μM U46619 for 0, 1, 2 and 4 h
at 37 °C. Cells were washed twice in ice-cold PBS prior to fixation in 3.7%
paraformaldehyde, 1× PBS, pH 7.4, for 15 min at room temperature. After
washing the cells in 1× TBS (20 mM Tris–HCl, pH 7.4, 0.1 M NaCl), non-
specific sites were blocked with Blocking Buffer (5% dried skimmed milk
powder in TBS) and then cells were incubated with anti-HA 101R antibody
(1:1000 in Blocking Buffer) for 1 h at room temperature. The antibody solution
was removed and the cells were washed twice in TBS, prior to incubation with
goat anti-mouse HRP (1:1000) for 45 min at room temperature. Thereafter, the
cells were washed trice in TBS and HA-tagged receptor expression was detected
colorimetrically at 650 nm using the K-Blue substrate [47].
To assess tonic internalization, 48 h post-seeding, cells were washed in
MEM, 10% FBS, prior to incubation in media containing mouse anti-HA 101R
(1 in 1000 dilution), at 4 °C for 1 h. Thereafter, the cells were rinsed briefly in
MEM to remove unbound antibody prior to incubating the cells at 4 °C and
37 °C for 2 h. Cells were washed twice in ice-cold PBS prior to fixation in 3.7%
paraformaldehyde, 1× PBS, pH 7.4, for 15 min at room temperature. After
washing the cells twice in 1× TBS (20 mMTris–HCl, pH 7.4, 0.1 MNaCl), non-
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the secondary goat anti-mouse HRP (1:1000) for 45 min at room temperature.
Detection of the HA-tagged receptors was via colorimetric K-Blue substrate
(Neogen Corp), as previously described [47].
2.8. Immunofluorescence and confocal microscopy
Cells were seeded onto poly-L-lysine pre-treated coverslips in 6-well plates
to achieve 60–70% confluency following 48 h incubation at 37 °C. Thereafter,
the media was changed to MEM, 10% FBS and cells were incubated with anti-
HA 101R (1 in 1000 dilution) at 4 °C for 1 h. Thereafter, unbound antibody was
removed by washing twice with media. To investigate agonist-induced inter-
nalization, cells were washed once with serum-free MEM prior to incubation
with 1 μM U46619 for 0, 2 and 4 h at 37 °C. To examine tonic internalization,
following labelling with anti-HA 101R (1 in 1000 dilution) at 4 °C for 1 h, cells
were washed briefly in MEM to remove unbound antibody prior to incubation at
4 °C and 37 °C for 2 h in MEM, 10% FBS.
After the appropriate incubation, cells were washed twice in ice-cold PBS prior
to fixation in 3.7% paraformaldehyde, 1× PBS, pH 7.4, for 15 min at room
temperature and thereafter washed three times with PBS. Cells to be permeabilizedFig. 1. Analysis of palmitoylation in HEK.TPα and HEK.TPβ cells. Panels A and B,
HEK.hIP (lane 4, positive control) cells were metabolically labelled for 2 h at 37 °C
TPβC373,377S cells (lane 3) and HEK.TPβC347,373,377S (lane 4) cells were metabolical
immunoprecipitated with anti-HA 101R and resolved by SDS-PAGE followed by ele
prior to fluorography for 60–90 days at −70 °C. Following fluorographic exposure, P
HA 3F10 peroxidase-conjugated antibody followed by chemiluminescent detection
markers (kDa) are indicated to the left and right of Panels A and D, respectively. Pa
TPβC347S, HEK.TPβC373,377S and HEK.TPβC347,373,377S cells relative to basal levels,
as mean fold increase in palmitoylation over basal levels ±S.E.M. and are expressed
The asterisks indicate that palmitoylation levels of TPα, TPβC347S, TPβC373,377S and T
⁎⁎, pb0.01; ⁎⁎⁎ pb0.005.were then incubated with 0.2%Triton X-100 in PBS for 10 min on ice followed by
washing in 1× TBS. Non-specific sites were blocked by incubating cells with
Blocking Buffer. Thereafter, receptors that had been previously labelled with the
anti-HA 101R antibody were labelled with the secondary goat anti-mouse FITC-
conjugated antibody solution. Cells were washed 3 times in 1× TBS, prior to
counterstainingwith propidium iodide (1 μg/ml, in H2O). Excess propidium iodide
was washed away with H2O prior to mounting coverslips in Vectashield (Vector
Laboratories) mounting medium. Slides were then imaged using Carl Zeiss Lazer
Scanning System LSM510 using Zeiss LSM Imaging software.
2.9. β-arrestin1 and β-arrestin2 co-localization with TPβ receptors
HEK 293 cells (10-cm dishes, 60–70% confluent) were transiently co-
transfected with pHM6-based plasmid encoding HA-tagged TPβ (365 ng), or its
mutated variants, along with either pEGFPN3:β-arrestin1 or pEGFPN1:β-
arrestin2, encoding green fluorescent protein (GFP)-tagged forms of the β-
arrestin1/2 (365 ng), in the presence of pADVA (270 ng) using the Effectene
(Qiagen) transfection reagent, as per manufacturer's instructions. Some 24 h
post-transfection, cells were replated onto fibronectin (50 μg/ml, 2 μg/cm2) pre-
coated glass coverslips (22 mm diameter) in 6-well plates and incubated for aHEK.TPβ (lane 1), HEK.TPα (lane 2), HEK 293 (lane 3, negative control) and
(Panel A). Panels C and D, HEK.TPβ (lane 1), HEK.TPβC347S (lane 2), HEK.
ly labelled for 2 h at 37 °C (Panel C). Thereafter, the HA-tagged receptors were
ctroblotting onto PVDF membrane. The blots (A and C) were soaked in Amplify
DVF membranes in A and C were screened by immunoblot analysis using anti-
to obtain Panels B and D, respectively. The positions of the molecular weight
nel E, the level of palmitoylation in HEK.hIP, HEK.TPα, HEK.TPβ, HEKHA.
in HEK 293 cells, was determined by Phosphorimage analysis. Data is presented
in arbitrary units. The data are representative of three independent experiments.
PβC347,373,377S cells were significantly lower than that of TPβwhere ⁎, pb0.05;
Table 1
Radioligand binding assays
Cell lines Kd Bmax
nM±S.E.M. pmol/mg protein±S.E.M.
HEK.TPβ 8.44±1.44 3.24±0.33
HEK.TPβC347S 7.81±3.22 4.16±0.86
HEK.TPβC373S 8.21±3.10 4.93±1.05
HEK.TPβC373,377S 8.57±2.44 4.16±2.06
HEK.TPβC347,373,377S 8.00±1.41 4.60±0.30
Saturation radioligand binding isotherms were carried out on HEK 293 cells
stably over-expressing HA epitope-tagged forms of TPβ and its variants using
the TP antagonist [3H] SQ29,548 (50.4 Ci/mmol, 0–40 nM) and 75 μg of whole
cell protein/assay. Radioligand binding data were analysed using GraphPrism 3
(GraphPad Software Inc.) to determine the Kd and Bmax values. Data presented
are the mean±S.E.M. of 3 independent experiments.
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dilution in MEM, 10% FBS) at 4 °C for 1 h. Unbound antibody was removed by
washing twice with media prior to incubating cells with 1 μMU46619 (prepared
in media) for 30 min at 37 °C. Thereafter, cells were fixed in 3.7% para-
formaldehyde, 1× PBS, pH 7.4, for 15 min at room temperature. Following
washing (3 times with 1× PBS), cells were permeabilized by incubation on ice
for 10 min in 0.2% Triton X-100 in PBS. Following washing twice in 1× TBS
(20 mM Tris–HCl, pH 7.4, 0.1 M NaCl) and further incubation for 30 min with
Blocking Buffer (5% dried skimmed milk powder in 1× TBS), HA-taggedFig. 2. Analysis of U46619-mediated [Ca2+]imobilization. HEK.TPβ (Panel A), HE
and HEK.TPβC347,373,377S (Panel E) cells, transiently co-transfected with pCMV5
where the ligand was added at times indicated by the arrows. The results are repres
intracellular Ca2+ mobilized (Δ[Ca2+]i, nM) as a function of time(s) following ligan
mobilization (nM±S.E.M.) for each cell line. The asterisk in Panel F indicates that
significantly lower than that of TPβ where ⁎, pb0.05.receptors, previously labelled with the anti-HA 101R antibody, were visualized
using the AlexaFluor594 goat anti-mouse IgG (1:1500) as secondary antibody.
Cells were washed trice in TBS, prior to counterstaining with DAPI (1 μg/ml, in
H2O). Excess DAPI was washed away with H2O prior to mounting coverslips in
Vectashield mounting medium. A Zeiss fluorescence microscope coupled with
AxioVision software (version 4.4) was used for acquiring multichannel, Z-stack
images (19 slices, 0.125 μM apart) with filters appropriate for enhanced GFP
and AlexaFluor 594 fluorescence. Subsequently, the multichannel, Z-stack
images were processed by AxioVision Deconvolution Analysis, with enabled
multichannel and Z-stack correction.
2.10. Data analyses
Radioligand binding data was analysed using GraphPad Prism V3.0 to
determine the Kd and Bmax values. Statistical analyses were carried out using the
unpaired Student's t test using the Statworks Analysis Package. p-Values of less
than or equal to 0.05 were considered to indicate a statistically significant
difference.3. Results
3.1. Palmitoylation of the human TXA2 receptor, TP
To investigate whether the human thromboxane (TX) A2
receptor (TP) isoforms are palmitoylated, human embryonicK.TPβC347S (Panel B), HEK.TPβC373S (Panel C), HEK.TPβC373,377S (Panel D)
:Gαq and preloaded with FURA2/AM, were stimulated with 1 μM U46619
entative profiles from 4 independent experiments and are plotted as changes in
d stimulation. Data presented in Panel F is plotted as mean changes in Δ[Ca2+]i
U46619-mediated [Ca2+]i mobilization by TPβ
C347S and TPβC347,373,377S was
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(HA) epitope-tagged forms of TPα and TPβ were metaboli-
cally labelled with [3H] palmitic acid. As a control, metabolic
labelling was also investigated in HEK.hIP cells stably over-
expressing HA-tagged human (h) prostacyclin receptor (hIP), a
GPCR previously confirmed to be palmitoylated [15].Metabolic
labelling and palmitoylation of both TPβ and the hIP was readily
detected as evidenced by the presence of broad radiolabelled
bands between 45 and 66 kDa markers in the immunoprecipi-
tates from HEK.TPβ and HEK.hIP cells (Fig. 1A, lanes 1 and 4,
respectively). In contrast, no metabolic labelling was associated
with the immunoprecipitates from HEK.TPα cells or from
control HEK 293 cells (Fig. 1A, lanes 2 and 3, respectively)
confirming that, unlike that of TPβ, the TPα isoform does not
undergo palmitoylation. Confirmation of equivalent expression
and efficient recovery of the hIP, TPα and TPβ receptors in their
respective immunoprecipitates were obtained by subsequentFig. 3. Effect of palmitoylation on agonist-induced internalization of TPβ. Panel
A, HEK.TPβ, HEK.TPβC347S, HEKHA.TPβC373S, HEK.TPβC373,377S and HEK.
TPβC347,373,377S cells were incubated with 1 μMU46619 at 37 °C for 0–4 h prior
to fixation and immunolabelling with anti-HA 101R. Results are expressed as
mean cell surface expression at each time point as a percentage of that at 0 h (%
cell surface expression±S.E.M., n=3) as a function time (h). Panel B, mean cell
surface expression following stimulation of cells with 1 μMU46619, 37 °C for 4 h
expressed as a percentage of that at 0 h (% cell surface expression±S.E.M., n=3).
The asterisks indicate that at 4 h, U46619-mediated loss of cell surface expression
of TPβC347S, TPβC373S, TPβC373,377S and TPβC347,373,377S was significantly
reduced relative to that of TPβ where ⁎⁎⁎, pb0.0001.screening of the PVDF membrane by immunoblot analysis
(Fig. 1B, lanes 1, 2 and 4, respectively) which also clearly
indicated that failure to detect palmitoylation of TPαwas not due
to failure of its immunoprecipitation.
From Phosphorimage analysis, it was evident that both TPβ
and the hIP were efficiently palmitoylated showing near
equivalent 4.36- and 4.82-fold increases in palmitoylation
relative to basal levels in HEK 293 cells, respectively (Fig. 1E).
The efficient metabolic labelling of the hIP is consistent with the
fact that this receptor undergoes palmitoylation at multiple Cys
residues within its C-tail domain [15]. In the case of TPβ, it is
notable that there are three cysteine residues within its unique
C-terminal tail domain which may potentially be palmitoylated,
possibly accounting for its near equivalent metabolic labelling
relative to that of the hIP (Fig. 1A and E). Thus, to investigate
the possible involvement of one or more of those Cys residues
in palmitoylation and the implications thereof for TPβ function,
site-directed mutagenesis was used to mutate Cys347, Cys373
and Cys377 to Ser residues, either individually and collec-
tively, to generate TPβC347S, TPβC373S, TPβC373,377S and
TPβC347,373,377S. HEK 293 cell stably over-expressing
TPβC347S, TPβC373S, TPβC373,377S and TPβC347,373,377S
were generated and initially characterised by saturation
radioligand binding analysis using the selective TP antagonist
SQ29,548. HEK.TPβC347S , HEK.TPβC373S , HEK.
TPβC373,377S and HEK.TPβC347,373,377S cells were confirmed
to display similar ligand binding characteristics (Kd and Bmax)
relative to HEK.TPβ cells and the mutations per se had no
affect on the receptor affinity (Table 1). It should be noted that
despite repeated attempts, it was not possible to generate
stable cell lines over-expressing TPβC377S.
To investigate whether Cys347 and/or Cys373,377 are actual
targets for TPβ palmitoylation, HEK.TPβC347S, HEK.
TPβC373,377S and HEK.TPβC347,373,377S cells were metabolically
labelled with [3H] palmitic acid. Palmitoylation of TPβ and, to a
lesser extent, of TPβC347S and TPβC373,377S was observed as
evidenced by the broad radiolabelled band between 45 and
66 kDa in their respective immunoprecipitates (Fig. 1C, lanes 1–
3, respectively). Phosphorimage analysis confirmed that while the
levels of metabolic labelling of both TPβC347S and TPβC373,377S
were significantly reduced relative to that of TPβ, palmitoylation
of either mutated receptor was not actually abolished (compare
4.36-, 2.01- and 2.68-fold increase in palmitoylation for TPβ,
TPβC347S and TPβC373,377S, respectively; Fig. 1E). In contrast,
the levels of metabolic labelling of TPβC347,373,377S (1.39-fold
increase) were significantly reduced relative to TPβ (Fig. 1C,
lanes 2 and 4, respectively; Fig. 1E) and, in fact, were found not to
be significantly greater than basal levels in immunoprecipitates
from HEK 293 cells. Confirmation of equivalent expression and
recovery of the TPβ, TPβC347S, TPβC373,377S and
TPβC347,373,377S receptors in their respective immunoprecipitates
was obtained by subsequent screening of the PVDFmembrane by
Western blot analysis (Fig. 1D, lanes 1–4, respectively) and
confirmed that failure, or any reductions, in detecting palmitoyla-
tion was not due to failure of the immunoprecipitation itself.
Thus, in summary, it is evident that TPβ is palmitoylated at
multiple Cys residues within its C-tail domain and that mutation
Fig. 4. Confocal microscopy of agonist-induced internalization. HEK.TPβ (Panel A), HEK.TPβC347S (Panel B), HEK.TPβC373,377S (Panel C) and HEK.
TPβC347,373,377S (Panel D) cells were with pre-labelled with anti-HA 101R, at 4 °C for 1 h, prior to stimulation with 1 μM U46619 at 37 °C for the times indicated.
Thereafter, following fixation, surface expression of the HA-tagged receptors was detected, under both non-permeabilizing and permeabilizing conditions, by
immunolabelling anti-mouse FITC-conjugated antibody. Images were captured using a Carl Zeiss Lazer Scanning System LSM510 and Zeiss LSM Imaging software.
The arrows show agonist-induced TPβ internalization as indicated by loss of cell surface HA-tagged TPβ detected in non-permeabilized cells and increased detection
of intracellular TPβ in permeabilized cells. The colour version of this figure is available online at www.sciencedirect.com.
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metabolic labelling confirming that palmitoylation occurs at both
Cys347 and Cys373,377. Moreover, we also observed a significant
reduction in the level of metabolic labelling of TPβC373S
confirming that Cys373 is specifically palmitoylated (data not
shown). However, as it was not possible to generate stable cell
lines over-expressing TPβC377S, we cannot conclude with
certainty whether Cys377 along with Cys373 is palmitoylated.
3.2. Effect of TPβC347S, TPβC373S, TPβC373,377S and
TPβC347,373,377S on intracellular signalling
Numerous studies have indicated that the covalent attach-
ment of palmitate has been implicated in the regulation of
receptor G protein coupling and subsequent downstream
signalling events [15,48]. To investigate whether palmitoyla-
tion has a role in Gq-coupled phospholipase (PL)Cβ activationby TPβ, we examined agonist-induced intracellular calcium
([Ca2+]i) mobilization by TPβ
C347S, TPβC373S, TPβC373,377S
and TPβC347,373,377S in response to the TXA2mimetic U46619.
Consistent with previous reports [30], HEK.TPβ cells,
transiently transfected with Gαq, showed efficient [Ca
2+]i
mobilization in response to U46619 (Fig. 2A). Stimulation of
TPβC373S or TPβC373,377S each showed efficient intracellular
signalling and it was found that U46619-mediated [Ca2+]i
mobilization by either TPβC373S or TPβC373,377S was not
significantly different to that of TPβ (Fig. 2C and D; p=0.94
and 0.61, respectively). On the other hand, while TPβC347S did
show a substantial signalling response (Fig. 2B), the level of
[Ca2+]i mobilization by TPβ
C347S was significantly reduced
relative to that of TPβ, TPβC373S or TPβC373,377S (Fig. 2F;
p=0.02). Moreover, consistent with this, U46619-induced
[Ca+]i mobilization by TPβ
C347,373,377S was also impaired
(Fig. 2E), showing significant reductions relative to that of
Fig. 5. Effect of palmitoylation on tonic internalization. HEK.TPβ, HEK.
TPβC347S, HEK. TPβC373S, HEK.TPβC373,377S and HEK.TPβC347,373,377S cells
were incubated in the presence of anti-HA 101R for 1 h at 4 °C. Thereafter,
following washing, cells were incubated at 4 °C or 37 °C for 2 h. Following
fixation, cell surface expression of the HA-tagged receptors was detected using
anti-mouse HRP conjugate antibody followed by colorimetric detection. Results
are expressed as cell surface expression at 2 h as percentage of that at 0 h at the
respective temperatures (% cell surface expression±S.E.M., n=3). The asterisks
indicates that at 37 °C, tonic internalization of TPβC373S, TPβC373,377S and
TPβC347,373,377S was significantly reduced compared to that of TPβ where
⁎, pb0.0001 and ⁎⁎, pb0.0005.
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there was no significant difference in signalling between
TPβC347S and TPβC347,373,377S (Fig. 2F; p=0.79). Taken
together, these data confirm that palmitoylation of TPβ plays
a significant role in mediating its efficient coupling to Gq/
PLCβ activation and, moreover, established that palmitoyla-
tion of Cys347 is specifically required for this regulation.
3.3. Effect of palmitoylation on agonist-induced internalization
of TPβ
TPβ, but not TPα, is widely reported to undergo significant
agonist-induced and tonic internalization, albeit through distinct
mechanisms [34,35]. Hence, to further investigate the function-
al consequences of TPβ palmitoylation, we also assessed and
compared agonist-induced internalization of TPβ, TPβC347S,
TPβC373S, TPβC373,377S and TPβC347,373,377S, initially using an
ELISA-based assay. Cells were treated with U46619 (1 μM)
over a 4 h period, prior to fixation and immunolabelling with
anti-HA 101R. Consistent with previous reports [34], TPβ
underwent efficient agonist-induced internalization such that
following 4 h exposure to U46619, its level of cell surface
expression was reduced by approx. 40% (Fig. 3). On the other
hand, mutation of any one of the Cys residues within the C-tail
domain of TPβ, be it Cys347, Cys373 or Cys377 either singly or
in combination, significantly impaired agonist-induced inter-
nalization (Fig. 3A). Specifically, following 4 h treatment with
U46619, the level of cell surface expression of TPβC347S,
TPβC347,373,377S, TPβC373S and TPβC373,377S had decreased by
less than 10–15% (Fig. 3B).
Agonist-induced internalization of TPβ, TPβC347S, TPβC373S,
TPβC373,377S and TPβC347,373,377S was also examined by
immunofluorescence and confocal microscopy (Fig. 4). Owing
to the fact that at any one time, even in the absence of agonist
stimulation, a significant proportion of TPβ expression is found
intracellularly, due at least in part to its tonic internalization and/
or retention within the endoplasmic reticulum [35,49], to
facilitate our studies cell surface receptors were initially
immunolabelled with anti-HA 101R prior to exposure of cells
with the agonist U46619. Immunolocalizations were then
captured under non-permeabilizing and permeabilizing condi-
tions at 0, 2 and 4 h (2 h data not shown throughout). In the
absence of agonist (0 h), there was a strong detection of HA-
tagged TPβ, TPβC347S, TPβC373,377S and TPβC347,373,377S at
their respective cell surfaces under both non-permeabilizing and
permeabilizing conditions (Fig. 4, Panels A–D, 0 h). In the
presence of U46619, cell surface expression of TPβ decreased
with time, as indicated by reduced immunodetection in HEK.
TPβ cells analysed in non-permeabilizing conditions, with a
corresponding increase in TPβ internalization detected following
permeabilization (Fig. 4A, 4 h). In permeabilized cells, TPβ
expression was observed intracellularly at 4 h confirming that the
HA-tagged TPβ had internalized from the cell surface into a
cytoplasmic compartment. Indeed, there was a distinct punctuate
staining within the perinuclear region, indicated by the arrow,
appearing at the 4 h time point (Fig. 4A, permeabilized, 4 h).
However, in contrast, the level of agonist-induced internalizationof TPβC347S was significantly impaired relative to that of the
wild type TPβwith no measurable decrease in surface expression
and no increase in intracellular expression of TPβC347S detected
under either non-permeabilizing or permeabilizing conditions
(Fig. 4B). Moreover, U46619-stimulation did not result in a
decrease in cell surface expression of TPβC373,377S and
TPβC347,373,377S in cells analysed under non-pemeabilizing
conditions, even following 4 h exposure to agonist (Fig. 4C
and D, respectively) with no decrease in cell surface expression
and no detection of internalized receptors when cells were
analysed under permeabilizing conditions (Fig. 4C and D, 4 h).
Similar results were observed for TPβC373S (data not shown).
Taken collectively, these data are consistent with previous
studies confirming that TPβ is readily internalized in response to
exposure to agonist [34]. However, in keeping with our ELISA-
based assays, when palmitoylation of TPβ is disrupted, as in the
case of either TPβC347S, TPβC373S, TPβC373,377S and/or
TPβC347,373,377S, the ability of TPβ to undergo agonist-induced
internalization is impaired, showing no significant reduction in
cell surface expression by either mutated variant.
3.4. Effect of palmitoylation on tonic internalization of TPβ
As stated, TPβ, but not TPα, has also been reported to undergo
tonic internalization through a temperature- and dynamin-
dependent but GRK- and β-arrestin-independent manner [35].
Hence, due to the reduced ability of the palmitoylation deficient
TPβmutants to undergo agonist-induced internalization, we next
sought to investigate the effect of palmitoylation on tonic
internalization. Again, cell surface receptors in HEK 293 cells
stably expressing TPβ, TPβC347S, TPβC373S, TPβC373,377S and
TPβC347,373,377S were pre-labelled at 4 °C with anti-HA 101R
prior to incubating the cells for 2 h at 4 °C and 37 °C, to evaluate
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Consistent with previous reports [35], TPβ readily underwent
tonic internalization as indicated by the 40% loss of cell surface
expression of TPβ observed at 37 °C without any loss in such
expression at 4 °C (Fig. 5). However, unlike that which occurred
for its agonist-induced internalization, it was found that TPβC347S
also underwent similar temperature-dependent tonic internaliza-
tion to levels similar to that of the wild type TPβ. Specifically, it
was found that cell surface expression of TPβC347S was reduced
by approx. 40% at 37 °C and to a level that was not significantly
different from that of the wild type TPβ (Fig. 5; p=0.32). On the
other hand, the level of tonic internalization of TPβC373S,
TPβC373,377S or TPβC347,373,377S was substantially impaired
relative to TPβ (Fig. 5) or TPβ C347S (pb0.0005) showing, on
average, only a 15% loss of cell surface receptor expression
following 2 h at 37 °C.
To further investigate the influence of palmitoylation on
internalization, we also monitored temperature-dependent tonicFig. 6. Confocal microscopy of tonic internalization. HEK.TPβ (Panel A), HEK.TPβ
D) cells were pre-labelled with anti-HA 101R at 4 °C for 1 h. Thereafter, following
paraformaldehyde. Cell surface expression of the HA-tagged receptors was detected
Images were captured using a Carl Zeiss Lazer Scanning System LSM510 and
internalization of TPβ and TPβC347S. The colour version of this figure is availableinternalization of TPβ and its palmitoylation defective variants
by confocal microscopy (Fig. 6). In brief, HEK 293 cell lines
stably over-expressing HA-tagged TPβ, TPβC347S, TPβC373,377S
or TPβC347,373,377S were pre-labelled with anti-HA 101R at 4 °C;
thereafter images were captured either directly (0 h), or following
incubation for 2 h at 4 °C or 37 °C under non-permeabilizing
(data not shown) and permeabilizing conditions (Fig. 6). At time
0 and following 2 h incubation at 4 °C, there was no evidence
of internalized receptor for TPβ, TPβC347S, TPβC373,377S or
TPβC347,373,377S with all of the immunolabelled receptors
showing cell surface expression. Following 2 h incubation at
37 °C, much of the expression of TPβ and TPβC347S was still
found at the cell surface, albeit at a substantially reduced level,
but in both cases a significant amount of the immunolabelled
receptors was present intracellularly consistent with their
temperature-dependent tonic internalization (Fig. 6A and B,
37 °C, indicated by arrows). As with the agonist-induced
internalization of TPβ, the cytoplasmic staining of TPβ andC347S (Panel B), HEK.TPβC373,377S (Panel C) and HEK.TPβC347,373,377S (Panel
washing, cells were incubated for 2 h at 4 °C or 37 °C, followed by fixation in
using anti-mouse FITC-conjugated antibody, under permeabilizing conditions.
Zeiss LSM Imaging software. The arrows show temperature-induced tonic
online at www.sciencedirect.com.
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However, in the case of TPβC373,377S or TPβC347,373,377S, there
was little evidence of tonic internalization at 37 °C with both
receptors being predominantly located at the cell surface (Fig. 6A
and B, 37 °C). These data, particularly when taken in
consideration with our ELISA-derived data, clearly indicates
that the ability of TPβC373,377S and TPβC347,373,377S to undergo
tonic internalization is severely impaired. Moreover, consistent
with the ELISA data herein, the level of tonic internalization of
TPβC373S following 2 h, or even more prolonged, incubation at
37 °C was severely impaired (data not shown).
Hence, in summary, whilst TPβ undergoes agonist-induced
and tonic internalization, disruption of palmitoylation by
mutating Cys347, Cys373 or Cys377, either singly or in com-
bination, abolishes agonist-induced internalization. However,
like TPβ, TPβC347S actually retains the ability to undergo tonic
internalization while that of TPβC373S, TPβC373,377S and
TPβC347,373,377S is substantially impaired.Fig. 7. Effect of β-arrestin on agonist-induced internalization. Panel A, HEK.
TPβ, HEK.TPβC347S, HEK.TPβC373S, HEK.TPβC373,377S and HEK.
TPβC347,373,377S cells, transiently co-transfected with pRK5.β-arrestin1,
pcDNA1.β-arrestin2 or, as a control, with the empty vector pcDNA were
incubated with U46619 (1 μM) at 37 °C for 4 h, prior to fixation and
immunolabelling with anti-HA 101R. Following fixation, cell surface
expression of the HA-tagged receptors was detected using anti-mouse HRP-
conjugated antibody followed by colorimetric detection. Results are expressed
as mean cell surface expression at 4 h as a percentage of that at 0 h (% cell
surface expression±S.E.M., n=3). The asterisk (⁎, pb0.05) indicates that over-
expression of β-arrestin1 and β-arrestin2 significantly reduced the level of cell
surface expression of TPβC347S in the presence of U46619. Panels B and C,
HEK.TPβ cells, transiently co-transfected with pRK5.β-arrestin1 (lane 2),
pcDNA1.β-arrestin2 (lane 3) or, as a control, with the empty vector pcDNA
(lane 1) were analysed by SDS-PAGE (50 μg whole cell protein analysed/lane)
followed by Western blot analysis using anti-β-arrestin1 (K-16: Panel B) and
anti-β-arrestin2 (N-16: Panel C). Data presented are representative immunoblots
from three independent experiments. The relative position of the 45 kDa
molecular size marker is indicated to the right of Panels B and C.3.5. Effect of β-arrestin1 and -2 on TPβC347S, TPβC373,377S and
TPβC347,373,377S internalization
As stated, it is widely reported that agonist-induced internal-
ization of TPβ shows a significant dependence on β-arrestin
recruitment post-receptor activation and may, for example, be
significantly reduced in the presence of dominant negative forms
of either β-arrestin1 or β-arrestin2 [34]. Therefore, to further
investigate the role of palmitoylation on TPβ internalization, we
transiently transfected β-arrestin1 and β-arrestin2 into HEK 293
cells stably over-expressing TPβ and its variant TPβC347S,
TPβC373,377S and TPβC347,373,377S with the view to assessing their
effect on agonist-mediated internalization. In the case of TPβ,
consistent with previous reports [34], over-expression of the wild
type forms of either β-arrestin1 or β-arrestin2 had no significant
effect on the overall level of U46619-induced internalization
following 4 h, as assessed by the ELISA-based internalization
assay (Figs. 3 and 7A). However, whilst TPβC347S does not
undergo significant agonist-induced internalization (Fig. 3), over-
expression ofβ-arrestin1 andβ-arrestin2 appeared to compensate
and resulted in a 30% loss of cell surface receptor following
exposure of cells to U46619 for 4 h (Fig. 7A, compare the level of
agonist-induced internalization in HEK.TPβC347S cells transient-
ly co-transfected with cDNA encoding β-arrestin1 and β-
arrestin2 relative to the empty vector; p=0.017 and p=0.042,
respectively). On the other hand, consistent with previous data
(Figs. 3 and 4), TPβC373,377S and TPβC347,373,377S did not
undergo agonist-induced internalization and over-expression of
either β-arrestin1 and β-arrestin2 had no significant effect on the
overall level of cell surface expression or internalization by either
receptor type (Fig. 7A, compare pcDNA to β-arrestin1 and -2,
pN0.2 and pN0.3, respectively). Over-expression of β-arrestin1
andβ-arrestin2 was confirmed in HEK.TPβ cells byWestern blot
analysis using anti-β-arrestin1 and anti-β-arrestin2 (Fig. 7B and
C, respectively).
To further assess the role of theβ-arrestins in agonist-induced
internalization of TPβ and its palmitoylation defective variants,
HEK 293 cells were transiently co-transfected with respective
plasmids encoding HA-tagged TPβ or its variants TPβC347S,
TPβC373S (data not shown), TPβC373,377S (data not shown) and
TPβC347,373,377S along with GFP-tagged forms of either β-
arrestin1 and β-arrestin2. HA-tagged cell surface receptors were
initially immunolabelled prior to stimulation with U46619 for
30 min; thereafter, cells were permeabilized and HA-tagged
receptor or GFP-tagged β-arrestin expression and co-localiza-
tions were captured by fluorescence microscopy (Fig. 8A and
B). While TPβ, TPβC347S and TPβC347,373,377S were each
clearly expressed on the cell surface in vehicle-treated cells
(Fig. 8A and B), TPβ was significantly internalized even
following exposure of cells to U46619 for 30min in the presence
of both GFP-tagged β-arrestin1 or β-arrestin2 (Fig. 8Ai and Bi).
Moreover in the presence of either GFP-tagged β-arrestin1 or β-
arrestin2, TPβC347S also underwent significant U46619-induced
internalization (Fig. 8Aii and Bii). On the other hand, neither
TPβC373S, TPβC373,377S (data not shown) nor TPβC347,373,377S
underwent internalization even in the presence of over-
expressed β-arrestins (Fig. 8Aiii and Biii). Consistent with
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exhibit diffuse uniform staining in the cytoplasm whilst β-
arrestin1, but not β-arrestin2, also showed significant nuclear
staining (Fig. 8A and B). Upon U46619-stimulation and in the
presence of TPβ, the GFP staining pattern associated with both
β-arrestin1 and β-arrestin2 was significantly altered. Specifi-
cally, GFP fluorescence became punctuate with a translocation
of both β-arrestin1 and β-arrestin2 from the cytoplasm to the
periphery of the cell, consistent with their co-localization and
interaction with agonist-activated TPβ on the cell surface
(Fig. 8Ai and Bi, respectively). Similarly, in the presence of
TPβC347S, both β-arrestin1 and β-arrestin2 showed transloca-
tion and enhanced co-localization with TPβC347S at the cell
surface in response to U46619-stimulation (Fig. 8Aii and Bii).
On the other hand, there was no evidence of β-arrestin1/2
translocation or receptor co-localization with TPβC373S,
TPβC373,377S (data not shown) or TPβC347,373,377S (Fig. 8Aiii
and Biii) in response to U46619-stimulation. Taken together,
these data demonstrated that over-expression of β-arrestin1 or
β-arrestin2 could compensate for the defect in agonist-induced
internalization of TPβC347S and suggest that palmitoylation of
TPβ, in particular at Cys347, is specifically required to mediate
β-arrestin1/2 translocation and receptor interaction in response
to agonist-stimulation.
4. Discussion
Palmitoylation is a prevalent feature of GPCRs with up to
80% of the superfamily estimated to contain at least one
cysteine in their C-tail domain, typically but not exclusively
proximal to transmembrane (TM) 7, which may potentially be
palmitoylated [5,7]. In this study, we sought to establish
whether TPα and/or TPβ are palmitoylated and to investigate
the functional consequences thereof. Whilst TPα does not
contain any cysteines within its unique C-tail domain, TPβ
possesses Cys347 close to the TM7/C-tail boundary and the
couplet Cys373 and Cys377 located some 30 amino acids from its
C-terminus. The results herein confirm that TPβ, but not TPα,
is palmitoylated. Furthermore, site-directed mutagenesis and in
vivometabolic labelling determined that TPβ is palmitoylated at
Cys347 and, to a lesser extent, at Cys373,377. Whilst palmitoyla-
tion was confirmed to occur at Cys373, attempts to further
ascertain whether Cys377, along with Cys373, is specifically
palmitoylated were not possible as stable cell lines over-
expressing TPβC377S could not be generated despite repeated
attempts.
A typical feature of palmitoylation is that it is viewed as a
reversible modification, with the propensity to regulate protein:
membrane or protein:protein association, protein localization
and/or function in a dynamic manner [1,6]. Moreover, severalFig. 8. Effect of palmitoylation on TPβ and β-arrestin co-localization. Panels A and B
(iii) TPβC347,373,377S along with pEGFPN3:β-arrestin1 (Panel A) or pEGFPN1:β-a
Thereafter, cells incubated with vehicle or U46619 (1 μM) for 30 min at 37 °C. Foll
with the AlexaFluor 594 anti-mouse IgG. Images were captured using the Zeiss Fluo
AxioVision Deconvolution analysis. The arrows show agonist-induced β-arrestin1 an
show the co-localization of the β-arrestins with the TPβ receptors. The colour versiGPCRs are known to undergo increased palmitoylation or
depalmitoylation in an agonist-dependent manner, modulating
receptor signalling potential in response to ligand engagement
[13,51,52]. In the current study, we found no evidence of altered
palmitoylation status of TPβ in response to agonist-stimulation
under the conditions of metabolic labelling employed and,
hence, data presented throughout are those generated in the
absence of ligand activation. However, as the process of
metabolic labelling and detection of palmitoylation is a rela-
tively inefficient process, with poor-signal-to-noise ratio, we
cannot exclude the possibility that TPβ palmitoylation is also
subject to dynamic modulation, such as in response to agonist-
engagement.
Numerous studies have indicated that the consequences of
palmitoylation of GPCRs are wide-ranging with many
aspects of receptor function being potentially implicated
including receptor processing, G protein/effector coupling,
phosphorylation and desensitization, sequestration and inter-
nalization, trafficking and/or protein turnover [1–5]. In
examining the functional consequences herein it was
established that palmitoylation of TPβ at Cys347 is required
for its efficient Gq-mediated PLCβ activation, the primary
effector of TP signalling. Specifically in the case in TPβC347S
and TPβC347,373,377S, there was a 30% reduction in U46619-
mediated [Ca2+]i mobilization compared to that of the wild
type TPβ. In contrast, U46619-mediated [Ca2+]i mobilization
by TPβC373S and TPβC373,377S was not significantly different
from TPβ, indicating that palmitoylation at Cys373 and/or
Cys377 does not influence Gq/PLCβ effector signalling.
The reduction in [Ca2+]i mobilization by TPβ
C347S or
TPβC347,373,377S was not due differences in their ligand
binding properties as each of the palmitoylation deficient
mutants displayed similar affinities for the selective TP
radioligand [3H]SQ29,548 and their overall level of expres-
sion was not significantly different to that of the wild type
TPβ. The specific requirement for palmitoylation at Cys347
for TPβ-mediated Gq/PLCβ activation is somewhat similar
to that previously reported for the hIP where it was
established that palmitoylation at Cys308, but not at Cys311,
is specifically required for its Gq/PLCβ coupling [15].
A number of studies have demonstrated that impairment of
receptor palmitoylation, as exemplified by the CCR5 receptor,
can result in the accumulation of GPCRs in intracellular stores
and in the lowering of cell surface expression [53]. In the case of
TPβ and its variants, as stated, we have established that
impairment of palmitoylation per se does not affect the overall
level of surface expression and does not appear to affect the
maturation or surface expression of TPβ. As TPβ is reported to
undergo agonist-dependent and agonist-independent or tonic
internalization, albeit through distinct mechanisms, we next, HEK 293 cells transiently co-transfected with (i) pHM6.TPβ, (ii) TPβC347S and
rrestin2 (Panel B) were immunolabelled with anti-HA 101R for 1 h at 4 °C.
owing fixation and permeabilization, cell surface HA-tagged TPs were labelled
rescence microscope with AxioVision software (version 4.4) and processed by
d β-arrestin2 translocation and TPβ internalization while the insets to the panels
on of this figure is available online at www.sciencedirect.com.
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internalization [34,35]. It was established that mutation of
Cys347, Cys373 or Cys377, either alone or in combination,
significantly impaired agonist-induced TPβ internalization
reducing the movement of the respective cell surface receptors
(TPβC347S, TPβC373S, TPβC373,377S or TPβC347,373,377S) into
intracellular compartment(s) relative to the wild type TPβ. On
the other hand, while tonic internalization by TPβC373S,
TPβC373,377S and TPβC347,373,377S was also significantly
impaired, it was striking that the variant TPβC347S retained
the ability to undergo tonic internalization. Furthermore, over-
expression of either β-arrestin1 or β-arrestin2 was able to
overcome the inability of TPβC347S to undergo agonist-induced
internalization, an effect not observed with the other palmitoyla-
tion deficient mutants including TPβC373S, TPβC373,377S and
TPβC347,373,377S. These data indicated a critical role for palmitoyla-
tion of Cys373,377 in both agonist-dependent and tonic internaliza-
tion of TPβ, while palmitoylation of TPβC347 is also required for
agonist-induced, but not tonic internalization.
Taken together, our results indicate that TPβ is palmitoylated
at 2 independent sites Cys347 and Cys373,377 separated by some
30 amino acid residues within its unique C-tail domain, to
regulate G protein coupling and receptor internalization. One of
the structural consequences of GPCR palmitoylation is that, by
increasing local hydrophobicity, the palmitoyl moiety(s) is
thought to become inserted into the membrane lipid bilayer
resulting in the formation of a putative fourth intracellular loop
within its C-tail domain, such as originally demonstrated for
rhodopsin [8,54,55]. Moreover, in certain cases, palmitoylation
at multiple independent sites, either alone or in combination
with other post-translational lipid modifications, has been
proposed to result in the formation of loop structures within
the C-tail domain of the given GPCR. For example, in the case
of the 5-hydroxytryptamine (5-HT)4(a) receptor, Ponimaskin
et al. [13,48] established that it undergoes palmitoylation at two
adjacent Cys residues (Cys328/Cys329) located proximal to TM7
but is also palmitoylated at Cys386, located one amino acid
residue from the C-terminus. They proposed that membrane
insertion of the palmitates at the proximal Cys328/Cys329 and
distal Cys386 residues resulted in the formation of a double loop
structure within the C-tail of the 5-HT4(a) receptor. While
palmitoylation deficient mutants of 5-HT4(a) receptor were
indistinguishable from the wild type receptor in mediating G
protein/effector signalling, mutation of the proximal and distal
residues was shown not only to differentially modulate
constitutive activation but also to modulate agonist-dependent
phosphorylation, desensitization and β-arrestin internalization
of the 5-HT4(a) receptor [13,48,56]. Similarly, it has been
proposed that the C-tail domain of the hIP also contains a
double loop structure anchored by dynamically regulated
proximal palmitoyl groups, at Cys308/Cys311, and by a distal
farnesyl isoprenoid permanently attached to its C-terminus and
that collectively these dual lipidations modulate G protein
coupling and effector signalling [15].
In order to rationalise the functional consequences of
palmitoylation of TPβ we present a model, as outlined in
Fig. 9, whereby it is proposed that palmitoylation of TPβ atCys347 and at Cys373,377 also leads to the formation of a double
loop structure within its C-tail domain. In our model, pal-
mitoylation at Cys347 and membrane insertion leads to the for-
mation of Loop Awhich, though not obligatory for Gq coupling,
leads to more efficient Gq/PLCβ activation and [Ca2+]i
mobilization. On the other hand, palmitoylation at the couplet
Cys373,377, leads to the formation of Loop B or C, depending on
whether Cys347 is also palmitoylated or not, respectively
(Fig. 9). Whilst palmitoylation at Cys373,377 is essential for
tonic internalization, palmitoylation at both Cys347 and
Cys373,377, leading to the formation of Loops A and B, is
required for agonist-induced internalization. In investigating the
mechanism of agonist-induced internalization of TPβ, Parent et
al., established that amino acid residues between 355 and 366
within its unique C-tail are essential for such β-arrestin-
dependent internalization [34]. Moreover, it has since been
established that Ser357 within the latter internalization domain is
a specific target for agonist-dependent G protein-coupled
receptor kinase (GRK)2/3 phosphorylation leading to β-arrestin
recruitment and TPβ desensitization and internalization [57]. It
is indeed noteworthy that both the latter agonist-dependent
internalization motif and the GRK phospho-target are located
between the palmitoylation sites at Cys347 and Cys373,377 within
the C-tail of TPβ. Hence in our model (Fig. 9) and as supported
by our experimental findings, we propose that palmitoylation of
TPβ at both Cys347 and Cys373,377, leading to the formation of
Loops A and B, would expose the agonist-induced internaliza-
tion motif and GRK phosphorylation site at Ser357 thereby
enabling β-arrestin recruitment. Whilst formation of Loop C by
palmitoylation at Cys373,377 alone, as observed in TPβC347S,
may also expose the internalizationmotif andGRK site at Ser357,
we propose that the C-tail is in an altered, less favorable
conformation for β-arrestin interaction and with reduced affinity
for β-arrestin binding. Hence, palmitoylation of Cys373,377
alone, as in the case of TPβC347S, yields a receptor with impaired
agonist-induced internalization owing to its reduced affinity for
β-arrestin1/2. Consistent with this, through our experimental
observations, over-expression of either β-arrestin1/2 overcame
this reduced affinity by TPβC347S and facilitated its internali-
zation in response to U46619-stimulation to levels that were
indistinguishable from those of the wild type TPβ. Moreover,
our immunolocalization data supported the agonist-dependent
recruitment of GFP-tagged forms of β-arrestin1 and β-arrestin2
to both the agonist-activated TPβ and TPβC347S but not to
TPβC347,373,377S, for example.
Our proposed model accounting for the role of palmitoyla-
tion in the regulation of β-arrestin-dependent agonist-induced
internalization of TPβ is consistent with a number of other
studies. In the case of the V2 vasopressin receptor, for example,
Charest and Bouvier established that palmitoylation enhances
the β-arrestin recruitment to the activated V2R, facilitating
internalization and other processes requiring the scaffolding
action of β-arrestin including activation of the mitogen-
activated protein kinase cascades [16]. In contrast, other studies
demonstrated that palmitoylation may actually inhibit β-arrestin
interaction [58]. For example, palmitoylation of the luteinizing
hormone/human chorionic gonadotropin receptor physically
Fig. 9. Model of palmitoylation of TPβ. Palmitoylation of TPβ occurs at 2 distinct sites through the attachment of palmitates at Cys347 and Cys373/377. Following
palmitoylation, it is proposed that membrane insertion of the palmitate moieties at Cys347 and Cys373/377 leads to the formation of a double loop structure within the C-
tail domain of TPβ referred to as Loop A and Loop B, respectively. A third conformation of the C-tail of TPβ occurs when Cys373,377, but not Cys347, is palmitoylated
resulting in the formation of Loop C, such as is found in TPβC347S. TPβC373,377S undergoes palmitoylation at Cys347 resulting in the formation of Loop A only while
TPβC347,373,377S does not contain Loops A, B or C. It was found that Loop A is required for efficient Gαq/PLCβ coupling as evidenced by the reduced agonist-induced
[Ca2+]i mobilization by TPβ
C347S and TPβC347,373,377S. It is proposed that Loop B is required for agonist-induced GRK phosphorylation at Ser357, followed by β-
arrestin recruitment and TPβ internalization, as evidenced by the impaired U46619-induced β-arrestin1/2 recruitment and internalization by TPβC347S, TPβC373,377S
and TPβC347,373,377S. Like the wild type TPβ, TPβC347S (which contains Loop C only) retains the ability to undergo tonic internalization while TPβC373,377S (which
contains Loop A only) or TPβC347,373,377S fails to undergo tonic or agonist-induced internalization. From these latter data, it is proposed that palmitoylation at Cys373
and/or Cys377, resulting in the formation of Loop C only (in TPβC347S) or Loop A plus Loop B (in wild type TPβ) is necessary to present a tonic internalization motif,
such as the proposed Y339X3Φ
343 [35], in the correct orientation for interaction with the internalization machinery.
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tion status of the receptor determines whether internalization
actually proceeds through a β-arrestin-dependent or indepen-
dent mechanism [58].
Whilst TPβ undergoes agonist-induced internalization via a
dynamin-, GRK2/3- and β-arrestin-dependent mechanism,
requiring an active or dynamic actin cytoskeleton [34–36],
tonic internalization is reported to occur, at least in part, through a
dynamin-dependent mechanism with no requirement for either
GRK phosphorylation or the β-arrestins [35]. In studies inves-
tigating the determinants of tonic internalization, Parent et al.,
identified the presence of a tonic internalization motif Y339
X3Φ
343, where X is any residue and Φ is a bulky hydrophobic
isoleucine, within the C-tail domain of TPβ. Hence, the critical
residues required for tonic internalization lie between residues
339 and 343 in close proximity to the Cys347 within the proposed
Loop A structure associated with TPβ (Fig. 9). Hence, it is
tempting to speculate that palmitoylation at Cys347 may modulate
tonic internalization of TPβ. Our experimental finding that
TPβC347S, in addition to the wild type TPβ, undergoes tonic
internalization suggests that the conformation of Loop C is
sufficient to present or orientate the latter motif for internalization
to occur. However, the fact that TPβC373,377S which containsLoop A, but not Loop B, does not undergo tonic internalization
leads us to propose that other unidentified sequence determinants
within Loop B, associated with TPβ, may also be required for
efficient tonic internalization and that the conformation of LoopC
may also orientate those sequences to facilitate that internaliza-
tion. The identities of those additional sequences required for
tonic internalization remain to be established.
In summary, various studies have indicated that many
GPCRs are palmitoylated and that the functional consequences
are diverse between receptors [3–5]. In this study we have
established that TPβ, but not TPα, is palmitoylated and that
palmitoylation occurs at distinct 2 sites, Cys347 and Cys373,377,
within its unique C-tail domain. Whilst palmitoylation at Cys347
is required for efficient Gq/PLCβ effector coupling, palmitoy-
lation at Cys373,377 is essential for receptor internalization, with
palmitoylation at Cys347 acting as a structural determinant of the
route by which the receptor is internalized, be it β-arrestin-
dependent or independent internalization. Due to the impor-
tance of TXA2 in vascular hemostasis, a clearer understanding
of how the TP isoforms are differentially regulated is critical.
Palmitoylation provides a dynamic and reversible post-
translational modification that can regulate TPβ, in terms of
its signalling, receptor desensitization and internalization and,
1070 H.M. Reid, B.T. Kinsella / Cellular Signalling 19 (2007) 1056–1070as such, acts as a major determinant of TPβ function. Moreover,
data presented herein provide a further rational explanation for
the clear functional and mechanistic differences between the
TPα and TPβ isoforms.
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